1. Vitamin D Regulates Cooperation Between Metadherin and Transcription Factor Lymphoid Enhancer-Binding Factor 1 in Prostate Cancer Development and Progression.
- Author
-
Huan Cheng, Yichun Wang, Chengjian Ji, Yong Wang, Da Zhong, and Ninghong Song
- Subjects
- *
THERAPEUTIC use of vitamin D , *PROTEINS , *EPITHELIAL-mesenchymal transition , *RESEARCH funding , *CELL adhesion molecules , *POLYMERASE chain reaction , *PROSTATE tumors , *TRANSCRIPTION factors , *FLUORESCENT antibody technique , *MICE , *BIOINFORMATICS , *ANIMAL experimentation , *WESTERN immunoblotting , *BIOLOGICAL assay , *DISEASE progression - Abstract
The incidence of prostate cancer is increasing, and its poor prognosis is associated with metadherin overexpression; however, its molecular mechanisms are unclear. This study used Western blot, quantitative real-time polymerase chain reaction, immunofluorescence, and tumorigenicity assays to investigate metadherin and epithelial-mesenchymal transition in prostate cancer. We found that metadherin was highly expressed in prostate cancer tissues, especially PC-3 cells. Metadherin overexpression promoted t epithelial-mesenchymal transition and tumor growth. Bioinformatics analysis and assays revealed that lymphoid enhancer-binding factor 1 directly activates the metadherin promoter. The epithelial- mesenchymal transition and tumorigenicity were suppressed by the silencing of lymphoid enhancer-binding factor 1; however, these effects were reversed by metadherin overexpression. Vitamin D treatment downregulated metadherin and lymphoid enhancer-binding factor 1, counteracting lymphoid enhancer-binding factor 1-induced metadherin upregulation. Our findings indicate that metadherin enhances epithelial-mesenchymal transition and tumorigenicity through lymphoid enhancer-binding factor 1, with vitamin D modulating this interaction in prostate cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF